Zentalis (ZNTL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$42.3M

Net income growth (year over year)

−57.35%

Net margin

—

Return on equity

−66.75%

EPS (trailing twelve months)

−$1.96

Book value per share

$2.00

P/E (trailing twelve months)

—

Price to book

1.66

Debt to assets

33.29%

Payout ratio

—

Dividend yield

—

Company profile

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

• How do I buy stock in Zentalis (ZNTL)?

  ZNTL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.